Navigation Links
Freezing prostate cancer does a man's body good
Date:3/9/2009

e gland; cryoablation was 100 percent effective in local control of the patient's disease," said Onik. He reported that 85 percent of the men retained sexual function. Of those who did not have previous prostate surgery, all remained continent. "Incontinence becomes a big issue with many patients. For some it's a more important side effect than impotence," said Onik.

According to Onik, the 3-D transperineal biopsy complements the focal cryoablation approach because earlier detection of smaller tumors increases the likelihood that a small tumor can be treated using cryoablation. In his study, Onik restaged 180 patients who had previously undergone TRUS mapping biopsies who were considering conservative management for their cancer. The results showed that 70 percent of the men would have their management changed by the new information provided by mapping. Through mapping, more than 50 percent of men who were diagnosed with cancer on one side of the prostate gland with traditional TRUS biopsy had undetected cancer on the other side as well, he said. Management of prostate cancer is in great part determined by the Gleason score, a cancer ranking method indicating tumor grade and stage and the extent and location of a patient's disease. "When we restaged the men, we found that 22 percent of them experienced an increase in their Gleason scoremeaning that they had a more aggressive cancer than was originally thought from their original biopsy. The 3-D mapping biopsy provided life-saving information," said Onik. "This biopsy technique allows us to map the location of the tumor with tremendous precision and has the potential to greatly affect the decisions we make about treating prostate cancer," Onik said. "The data are unequivocal. If you're doing 'watchful waiting,' get mapped. If you're having radiation or hormone therapy or thinking about getting a 'nerve-sparing' radical prostatectomy, get mapped. If TRUS doesn't show all the cancer that's present, you're not
'/>"/>

Contact: Maryann Verrillo
mverrillo@SIRweb.org
703-460-5572
Society of Interventional Radiology
Source:Eurekalert

Page: 1 2 3 4 5

Related biology news :

1. Inactivity of proteins behind longer shelf life when freezing
2. Freezing kidney cancer: Hot treatment should be new gold standard for destroying small tumors
3. University of Minnesota study refutes belief that black men have more aggressive prostate cancer
4. New prostate cancer research findings
5. Leading researchers to reveal comprehensive dos and donts for prostate cancer
6. New genetic variant associated with prostate cancer in African-Americans
7. Safeway Inc. and PCF to fund landmark prostate cancer research collaboration
8. Nanomedicine research for prostate cancer supported by $5 million gift
9. Prostate cancer: Watchful wait or vaccinate?
10. New, noninvasive prostate cancer test beats PSA in detecting prostate cancer
11. Potential association of type 2 diabetes genes with prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/6/2015)... Conn. , Apr. 6, 2015 NXT-ID, ... "Company"), a biometric authentication company focused on the ... has filed provisional patent 62/143028 for ... COMMUNICATIONS AND ENERGY TRANSFER  NXT-ID introduces a ... payments. This patent surrounds the use of miniature ...
(Date:4/2/2015)... GOTHENBURG, Sweden , April 2, 2015 ... revenues for Q1 2015 attributed to somewhat higher than ... company in the year-end report 2014 that revenues for ... MSEK that the company reported for Q4 2014. The ... continue to be negative. The complete interim report will ...
(Date:4/1/2015)... BOSTON , April 1, 2015   Medisafe ... 1.5 million users across iOS and ... has begun integrating biofeedback into the platform to allow ... health outcomes. For the first time, patients will be ... missing a dose impacts important biometrics, such as glucose ...
Breaking Biology News(10 mins):NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4Fingerprint Cards Revises Revenues for Q1 2015 2Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2
... today in Science , researchers from Cambridge, Glasgow ... in how transcription factors, the proteins that bind to ... function over large evolutionary distances. The text books ... they regulate by binding to short, sequence-specific lengths of ...
... reef ecosystems are highly valued for their diverse ... reef fishing and tourism industries, but they are ... over-exploitation. The National Institute for Mathematical ... for its Investigative Workshop, Modeling Reef Ecosystems, to ...
... info@engconfintl.org ) and the Cell Culture Engineering ... proud to announce Prof. Michael J. Betenbaugh, ... Culture Engineering Award.,Mike Betenbaugh ( http://www.jhu.edu/chembe/faculty-template/MichaelBetenbaugh.html ) ... at Johns Hopkins University, Baltimore, MD, USA. ...
Cached Biology News:Rewiring of gene regulation across 300 million years of evolution 2Michael Betenbaugh wins 2010 Cell Culture Engineering award 2
(Date:4/30/2015)... 2015 WuXi PharmaTech (Cayman) Inc. ("WuXi" or ... contract R&D services provider, today announced that its board ... dated April 29, 2015, from a consortium (the "Consortium") ... founder, chairman and chief executive officer of the Company, ... a transaction (the "Transaction") involving the acquisition of all ...
(Date:4/30/2015)... April 30, 2015 SureClinical, a leader ... I. Morris has joined SureClinical’s executive team as Chief ... biotech and technology executive with over 25 years in ... companies. , Ms. Morris joins SureClinical from Marrone ... She was CFO of MBI from its founding in ...
(Date:4/29/2015)... April 30, 2015 According to ... Market by Product (Portable & Non-Portable), Component (Accelerometer, ... Automotive, Chemical, Metal & Mining, & Others), & ... market is expected to reach $1,453.76 Million by ... 71 market data tables and 92 figures spread ...
(Date:4/29/2015)... April 29, 2015   Doximity , the leading ... US doctors as members, announced a new, instant method ... Using Doximity." With one click, all US physicians can ... vitae (CV) for an open job opportunity, and a ... Eighty seven percent of physicians are open to ...
Breaking Biology Technology:WuXi PharmaTech Announces Receipt of Proposal 2WuXi PharmaTech Announces Receipt of Proposal 3WuXi PharmaTech Announces Receipt of Proposal 4WuXi PharmaTech Announces Receipt of Proposal 5WuXi PharmaTech Announces Receipt of Proposal 6Julie I. Morris Joins SureClinical as Chief Financial Officer 2Vibration Monitoring Equipment (Portable & Non-Portable) Market worth $1,453.76 Million by 2020 - New Report by MarketsandMarkets 2Vibration Monitoring Equipment (Portable & Non-Portable) Market worth $1,453.76 Million by 2020 - New Report by MarketsandMarkets 3Vibration Monitoring Equipment (Portable & Non-Portable) Market worth $1,453.76 Million by 2020 - New Report by MarketsandMarkets 4Doximity Offering Hospitals Easy, Efficient Physician Application Tool 2
... at American Society of Clinical Oncology , , ... presented data demonstrating the use of ChemoFX(R), a chemosensitivity ... the colorectal cancer cells of individual patients. Results ... colorectal cultures tested, eight percent were responsive to cetuximab, ...
... KVISTGAARD, Denmark, June 1 Detailed ... Saturday at the,ASCO Annual Meeting in Orlando. The presentation was ... School , and the Dana-Farber Cancer,Institute who is also the ... The more detailed analysis supports the headline data that were ...
... Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY ) ... intravenous REOLYSIN(R) in patients with sarcomas metastatic to the lung ... Clinical Oncology (ASCO) annual meeting. The meeting is being held ... , The presentation, entitled "A Phase II Study of Intravenous ...
Cached Biology Technology:Laboratory Test May Predict Effectiveness of ERBITUX(R) for Individual Colorectal Cancer Patients 2Laboratory Test May Predict Effectiveness of ERBITUX(R) for Individual Colorectal Cancer Patients 3PROSTVAC(TM) Data Presented at the ASCO Meeting Demonstrates the Potential for Significant Increases in Life Expectancy in Late-Stage Prostate Cancer 2PROSTVAC(TM) Data Presented at the ASCO Meeting Demonstrates the Potential for Significant Increases in Life Expectancy in Late-Stage Prostate Cancer 3Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at ASCO Annual Meeting 2Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at ASCO Annual Meeting 3
Cytofix Buffer 100 mls...
Cytofix/Cytoperm Plus Kit with GolgiPlug 250 Tests...
Rabbit polyclonal to 3-Ethynylestradiol ( Abpromise for all tested applications). Antigen: Ethynylestradiol conjugated to BSA....
Antibody specific for histone H3 acetylated at any of the five N-terminal lysine residues. Rabbit polyclonal serum. Antigen: Synthetic peptide derived from histone H3 N-terminal region, mulitpliy...
Biology Products: